Simultaneous quantification of d- vs. l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: Differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents

Journal of Neuroscience Methods

Volumn 202, Issue 2, 2011, Pages 143-157

  Gobert, Alain ^a   Rivet, Jean Michel ^a   Billiras, Rodolphe ^a   Parsons, Francesca ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Astrocyte; Cystine glutamate antiporter; D serine; Glycine transporter; NMDA receptor; Red Bull

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; ALANINE; AMINO ACID; AMINOOXYACETIC ACID; ARGININE; BACLOFEN; CITRULLINE; DEXTRO SERINE; DIZOCILPINE; FLUOROACETIC ACID; GLUTAMIC ACID; GLUTAMINE; GLYCINE; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID; NIPECOTIC ACID; PHOSPHOETHANOLAMINE; SARCOSINE; SERINE; TAURINE; TYROSINE; VIGABATRIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; BEVERAGE; CELL METABOLISM; DIALYSATE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NERVE CELL; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

AMINO ACIDS; ANIMALS; EXCITATORY AMINO ACID AGENTS; MALE; MICRODIALYSIS; N-METHYLASPARTATE; PREFRONTAL CORTEX; RATS; RATS, WISTAR;

EID: 81055156867     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.08.040     Document Type: Article

References (118)

1. Adage T., Trillat A.C., Quattropani A., Perrin D., Cavarec L., Shaw J., et al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 2008, 18:200-214.
2. Alberati D., Moreau J.L., Mory R., Pinard E., Wettstein J.G. Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential. Pharmacol Biochem Behav 2010, 97:185-191.
3. Albrecht J., Schousboe A. Taurine interaction with neurotransmitter receptors in the CNS: an update. Neurochem Res 2005, 30:1615-1621.
4. Alford C., Cox H., Wescott R. The effects of red bull energy drink on human performance and mood. Amino Acids 2001, 21:139-150.
5. Balan L., Foltyn V.N., Zehl M., Dumin E., Dikopoltsev E., Knoh D., et al. Feedback inactivation of d-serine synthesis by NMDA receptor-elicited translocation of serine racemase to the membrane. Proc Natl Acad Sci USA 2009, 106:7589-7594.
6. Ballini C., Corte L.D., Pazzagli M., Colivicchi M.A., Pepeu G., Tipton K.F., et al. Extracellular levels of brain aspartate, glutamate and GABA during an inhibitory avoidance response in the rat. J Neurochem 2008, 106:1035-1043.
7. Beart P.M., O'Shea R.D. Transporters for l-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol 2007, 150:5-17.
8. - cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol 2011, doi:10.1111/j.1476-5381.2011.01480.x.
9. Bridges R.J., Esslinger C.S. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 2005, 107:271-285.
10. Buck R.H., Krummen K. High-performance liquid chromatographic determination of enantiomeric amino acids and amino alcohols after derivatization with o-phthaldialdehyde and various chiral mercaptans. Application to peptide hydrolysates. J Chromatogr 1987, 387:255-265.
11. Burnet P.W., Hutchinson L., von Hesling M., Gilbert E.J., Brandon N.J., Rutter A.R., et al. Expression of d-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophr Res 2008, 102:283-294.
12. B receptors modulate NMDA receptor calcium signals in dendritic spines. Neuron 2010, 66:101-113.
13. Chen P.E., Geballe M.T., Stansfeld P.J., Johnston A.R., Yuan H., Jacob A.L., et al. Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-d-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol 2005, 67:1470-1484.
14. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007, 33:797-804.
15. Coyle J.T. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res 2006, 10:221-233.
16. 1 and impairs its internalization. J Neurochem 2005, 95:1047-1458.
17. Curry K., Stasio M.J. The effects of energy drinks alone or with alcohol on neuropsychological functioning. Hum Psychopharmcol Clin Exp 2009, 24:473-481.
18. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65:1-105.
19. Danysz W., Parsons C.G. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998, 50:597-664.
20. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011, 36:78-86.
21. Del Arco A., Segovia G., Fuxe K., Mora F. Changes in dialysate concentrations of glutamate and GABA in the brain: an index of volume transmission mediated actions?. J Neurochem 2003, 85:23-33.
22. Del Arco A., Segovia G., Prieto L., Mora F. Endogenous glutamate-taurine interaction in striatum and nucleus accumbens of the freely moving rat: studies during the normal process of aging. Mech Ageing Dev 2001, 122:401-414.
23. Docherty M., Bradford H.F., Wu J.Y. Co-release of glutamate and aspartate from cholinergic and GABAergic synaptosomes. Nature 1987, 330:64-66.
24. Drew K.L., Pehek E.A., Rasley B.T., Ma Y.L., Green T.K. Sampling glutamate and GABA with microdialysis: suggestions on how to get the dialysis membrane closer to the synapse. J Neurosci Methods 2004, 140:127-131.
25. Dunlop D.S., Neidle A. Regulation of serine racemase activity by amino acids. Brain Res Mol Brain Res 2005, 133:208-214.
26. El Idrissi A., Boukarrou L., Splavnyk K., Zavyalova E., Meehan E.F., L'Amoreaux W. Functional implication of taurine in aging. Adv Exp Med Biol 2009, 643:199-206.
27. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23:91-101.
28. Errico F., Napolitano F., Nisticò R., Centonze D., Usiello A. d-aspartate: an atypical amino acid with neuromodulatory activity in mammals. Rev Neurosci 2009, 20:429-440.
29. Eulenburg V., Gomeza J. Neurotransmitter transporters expressed in glial cells as regulators of synapse function. Brain Res Rev 2010, 63:103-112.
30. Fonnum F., Johnsen A., Hassel B. Use of fluorocitrate and fluoroacetate in the study of brain metabolism. Glia 1997, 21:106-113.
31. Forero D.A., van der Ven K., Callaerts P., Del-Favero J. MiRNA genes and the brain: implications for psychiatric disorders. Hum Mutat 2010, 31:1-10.
32. Frantz K., Harte M., Ungerstedt U., O' Connor W.T. A dual probe characterization of dialysate amino acid levels in the medial prefrontal cortex and ventral tegmental area of the awake freely moving rat. J Neurosci Methods 2002, 119:109-119.
33. Fujihira T., Kanematsu S., Umino A., Yamamoto N., Nishikawa T. Selective increase in the extracellular d-serine contents by d-cycloserine in the rat medial frontal cortex. Neurochem Int 2007, 51:233-236.
34. Fukushima T., Kawai J., Imai K., Toyo'oka T. Simultaneous determination of d- and l-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed Chromatogr 2004, 18:813-819.
35. B receptor activation in cortical circuits?. Adv Pharmacol 2010, 58:175-204.
36. Gravius A., Pietraszek M., Dekundy A., Danysz W. Metabotropic glutamate receptors as therapeutic targets for cognitive disorders. Curr Top Med Chem 2010, 10:187-206.
37. Gundersen V. Co-localization of excitatory and inhibitory transmitters in the brain. Acta Neurol Scand Suppl 2008, 188:29-33.
38. Gyimesi-Forrás K., Leitner A., Akasaka K., Lindner W. Comparative study on the use of ortho-phthalaldehyde, naphthalene-2,3-dicarboxaldehyde and anthracene-2,3-dicarboxaldehyde reagents for alpha-amino acids followed by the enantiomer separation of the formed isoindolin-1-one derivatives using quinine-type chiral stationary phases. J Chromatogr A 2005, 1083:80-88.
39. Halassa M.M., Fellin T., Haydon P.G. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 2007, 13:54-63.
40. Hascup E.R., Hascup K.N., Stephens M., Pomerleau F., Huettl P., Gratton A., et al. Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J Neurochem 2010, 115:1608-1620.
41. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J 2010, 4:10-19.
42. Hashimoto A., Oka T., Nishikawa T. Extracellular concentration of endogenous free d-serine in the rat brain as revealed by in vivo microdialysis. Neuroscience 1995, 66:635-643.
43. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21:7463-7473.
44. Hussy N., Deleuze C., Desarmenien M.G., Moos F.C. Osmotic regulation of neuronal activity: a new role for taurine and glial cells in hypothalamic neuroendocrine structure. Prog Neurobiol 2000, 62:113-134.
45. Jacobs W.A., Leburg M.W., Madaj E.J. Stability of o-phthalaldehyde-derived isoindoles. Anal Biochem 1986, 156:334-340.
46. Javitt D.C. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 2006, 19:151-157.
47. Jay T.M., Thierry A.M., Wiklund L., Glowinski J. Excitatory amino acid pathway from the hippocampus to the prefrontal cortex. Contribution of AMPA receptors in hippocampo-prefrontal cortex transmission. Eur J Neurosci 1992, 4:1285-1295.
48. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
49. Jhamandas K.H., Boegman R.J., Beninger R.J., Miranda A.F., Lipic K.A. Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox Res 2000, 2:139-155.
50. Kanematsu S., Ishii S., Umino A., Fujihira T., Kashiwa A., Yamamoto N., et al. Evidence for involvement of glial cell activity in the control of extracellular d-serine contents in the rat brain. J Neural Transm 2006, 113:1717-1721.
51. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res Bull 2010, 83:108-121.
52. Kennedy R.T., Thompson J.E., Vickroy T.W. In vivo monitoring of amino acids by direct sampling of brain extracellular fluid at ultralow flow rates and capillary electrophoresis. J Neurosci Methods 2002, 114:39-49.
53. Labrie V., Roder J.C. The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 2010, 34:351-372.
54. Lada M.W., Vickroy T.W., Kennedy R.T. Evidence for neuronal origin and metabotropic receptor-mediated regulation of extracellular glutamate and aspartate in rat striatum in vivo following electrical stimulation of the prefrontal cortex. J Neurochem 1998, 70:617-625.
55. Ladera C., del Carmen Godino M., José Cabañero M., Torres M., Watanabe M., Luján R., et al. Pre-synaptic GABA receptors inhibit glutamate release through GIRK channels in rat cerebral cortex. J Neurochem 2008, 107:1506-1517.
56. Largo C., Cuevas P., Somjen G.G., Martín del Río R., Herreras O. The effect of depressing glial function in rat brain in situ on ion homeostasis, synaptic transmission, and neuron survival. J Neurosci 1996, 16:1219-1229.
57. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 2008, 165:1585-1593.
58. Li H., Li C., Yan Z.Y., Yang J., Chen H. Simultaneous monitoring multiple neurotransmitters and neuromodulators during cerebral ischemia/reperfusion in rats by microdialysis and capillary electrophoresis. J Neurosci Methods 2010, 189:162-168.
59. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008, 31:234-242.
60. López-Gil X., Babot Z., Amargós-Bosch M., Suñol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32:2087-2097.
61. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
62. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
63. B receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord 2002, 1:191-213.
64. Millan M.J. The neurobiology and control of anxious states. Prog Neurobiol 2003, 70:83-244.
65. Millan M.J. N-methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 2005, 179:30-53.
66. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110:135-370.
67. Millan M.J., Panayi F., Rivet J.M., Di Cara B., Cistarelli L., Billiras R., et al. The role of microdialysis in drug discovery: focus on antipsychotic agents. Handbook of microdialysis: methods, applications and perspectives 2007, 16:485-511. Elsevier, Amsterdam.
68. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
69. Möhler H., Rudolph U., Boison D., Singer P., Feldon J., Yee B.K. Regulation of cognition and symptoms of psychosis: focus on GABA(A) receptors and glycine transporter 1. Pharmacol Biochem Behav 2008, 90:58-64.
70. Moroni F., Cozzi A., Carpendo R., Cipriani G., Veneroni O., Izzo E. Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus. Neuropharmacology 2005, 48:788-795.
71. Mothet J.P., Pollegioni L., Ouanounou G., Martineau M., Fossier P., Baux G. Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter d-serine. Proc Natl Acad Sci USA 2005, 102:5606-5611.
72. Nagy K., Marko B., Zsilla G., Matyus P., Pallagi K., Szabo G., et al. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem Res 2010, 35:2096-2106.
73. Németh H., Toldi J., Vécsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl 2006, 70:285-304.
74. Oja S.S., Saransaari P. Modulation of taurine release by glutamate receptors and nitric oxide. Prog Neurobiol 2000, 62:407-425.
75. Oliet S.H., Mothet J.P. Regulation of N-methyl-d-aspartate receptors by astrocytic d-serine. Neuroscience 2009, 158:275-283.
76. Parrot S., Bert L., Mouly-Badina L., Sauvinet V., Colussi-Mas J., Lambás-Señas L., et al. Microdialysis monitoring of catecholamines and excitatory amino acids in the rat and mouse brain: recent developments based on capillary electrophoresis with laser-induced fluorescence detection-a mini-review. Cell Mol Neurobiol 2003, 23:793-804.
77. Patel A.B., Rothman D.L., Cline G.W., Behar K.L. Glutamine is the major precursor for GABA synthesis in rat neocortex in vivo following acute GABA-transaminase inhibition. Brain Res 2001, 919:207-220.
78. Perea G., Navarrete M., Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009, 32:421-431.
79. Perry K.W., Falcone J.F., Fell M.J., Ryder J.W., Yu H., Love P.L., et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008, 55:743-754.
80. Phillips J.B., Cox B.M. Release of endogenous glutamate and gamma-aminobutyric acid from rat striatal tissue slices measured by an improved method of high performance liquid chromatography with electrochemical detection. J Neurosci Methods 1997, 77:211-220.
81. 1 glycine transporters expressed in neurons. J Neurochem 2010, 114:647-653.
82. Rea K., Cremers T.I., Westerink B.H. HPLC conditions are critical for the detection of GABA by microdialysis. J Neurochem 2005, 94:672-679.
83. Reissig C.J., Strain E.C., Griffiths R.R. Caffeinated energy drinks-a growing problem. Drug Alcohol Depend 2009, 99:1-10.
84. Rosenberg D., Kartvelishvily E., Shleper M., Klinker C.M., Bowser M.T., Wolosker H. Neuronal release of d-serine: a physiological pathway controlling extracellular d-serine concentration. FASEB J 2010, 24:2951-2961.
85. Rotaru D.C., Yoshino H., Lewis D.A., Ermentrout G.B., Gonzalez-Burgos G. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. J Neurosci 2011, 31:142-156.
86. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
87. Sauvinet V., Parrot S., Benturquia N., Bravo-Moratón E., Renaud B., Denoroy L. In vivo simultaneous monitoring of gamma-aminobutyric acid, glutamate, and l-aspartate using brain microdialysis and capillary electrophoresis with laser-induced fluorescence detection: Analytical developments and in vitro/in vivo validations. Electrophoresis 2003, 24:3187-3196.
88. Schousboe A., Waagepetersen H.S. GABA: homeostatic and pharmacological aspects. Prog Brain Res 2007, 160:9-19.
89. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002, 303:1-10.
90. Shao Z., Kamboj A., Anderson C.M. Functional and immunocytochemical characterization of d-serine transporters in cortical neuron and astrocyte cultures. J Neurosci Res 2009, 87:2520-2530.
91. Shimamoto K. Glutamate transporter blockers for elucidation of the function of excitatory neurotransmission systems. Chem Rec 2008, 8:182-199.
92. Shimazaki T., Kaku A., Chaki S. d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology 2010, 209:263-270.
93. Shirayama Y., Obata T., Matsuzawa D., Nonaka H., Kanazawa Y., Yoshitome E., et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010, 49:2783-2790.
94. Smith S., Sharp T. Measurement of GABA in rat brain microdialysates using o-phthaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection. J Chromatogr 1994, 652:228-233.
95. Speciale C., Wu H.Q., Gramsbergen J.B., Turski W.A., Ungerstedt U., Schwarcz R. Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid. Neurosci Lett 1990, 116:198-203.
96. Stobaugh J.F., Repta A.J., Sternson L.A., Garren K.W. Factors affecting the stability of fluorescent isoindoles derived from reaction of o-phthalaldehyde and hydroxyalkylthiols with primary amines. Anal Biochem 1983, 135:495-504.
97. 2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings. J Neurochem 2003, 84:522-532.
98. Swanson R.A., Graham S.H. Fluorocitrate and fluoroacetate effects on astrocyte metabolism in vitro. Brain Res 1994, 664:94-100.
99. Swartz K.J., During M.J., Freese A., Beal M.F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990, 10:2965-2973.
100. Timmerman W., Westerink B.H. Brain microdialysis of GABA and glutamate: what does it signify?. Synapse 1997, 27:242-261.
101. Tong X., Ratnaraj N., Patsalos P.N. Vigabatrin extracellular pharmacokinetics and concurrent gamma-aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis. Epilepsia 2009, 50:174-183.
102. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010, 16:522-537.
103. Turiák G., Volicer L. Stability of o-phthalaldehyde-sulfite derivatives of amino acids and their methyl esters: electrochemical and chromatographic properties. J Chromatogr A 1994, 668:323-329.
104. van der Zeyden M., Oldenziel W.H., Rea K., Cremers T.I., Westerink B.H. Microdialysis of GABA and glutamate: analysis, interpretation and comparison with microsensors. Pharmacol Biochem Behav 2008, 90:135-147.
105. Vance J.E. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 2008, 49:1377-1387.
106. Verleysdonk S., Martin H., Willker W., Leibfritz D., Hamprecht B. Rapid uptake and degradation of glycine by astroglial cells in culture: synthesis and release of serine and lactate. Glia 1999, 27:239-248.
107. Verrall L., Burnet P.W., Betts J.F., Harrison P.J. The neurobiology of d-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry 2010, 15:122-137.
108. B receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release. J Neural Transm 2008, 115:1401-1411.
109. Walls A.B., Eyjolfsson E.M., Smeland O.B., Nilsen L.H., Schousboe I., Schousboe A., et al. Knockout of GAD65 has major impact on synaptic GABA synthesized from astrocyte-derived glutamine. J Cereb Blood Flow Metab 2011, 31:494-503.
110. Westerink B.H.C., Cremers T.I.F.H. Handbook of microdialysis: Methods, Applications and Perspectives 2007, 16. Elsevier, Amsterdam, pp. 1-697.
111. Wolosker H. Serine racemase and the serine shuttle between neurons and astrocytes. Biochim Biophys Acta 2011; in press. doi:10.1016/j.bbapap.2011.01.001.
112. Wu J.Y., Prentice H. Role of taurine in the central nervous system. J Biomed Sci 2010, 17(Suppl. 1):S1.
113. Yang C.R., Svensson K.A. Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008, 120:317-332.
114. Yang J.H., Wada A., Yoshida K., Miyoshi Y., Sayano T., Esaki K., et al. Brain-specific Phgdh deletion reveals a pivotal role for l-serine biosynthesis in controlling the level of d-serine, an N-methyl-d-aspartate receptor co-agonist, in adult brain. J Biol Chem 2010, 285:41380-41390.
115. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in post-mortem brains from schizophrenic patients. Schizophr Res 2000, 42:7-17.
116. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., et al. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci 2006, 26:3169-3181.
117. Yonezawa Y., Kuroki T., Kawahara T., Tashiro N., Uchimura H. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 1998, 341:45-56.
118. Zmarowski A., Wu H.Q., Brooks J.M., Potter M.C., Pellicciari R., Schwarcz R., et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 2009, 29:529-538.